# DMAAU (Drugs Made in America Acquisition Corp.) - SEC EDGAR Financial Statements

> Drugs Made in America Acquisition Corp. reported $147.5M in total assets and net income of $5.16M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/DMAAU
- Markdown: https://convexityos.com/fundamentals/DMAAU.md
- SEC CIK: 0002028614
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:42 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002028614&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$2.47M | Operating profit |
| Net Income | FY 2025 | $5.16M | GAAP bottom line |
| Diluted EPS | FY 2025 | -- | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $17K | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 |
| --- | --- |
| **Operating Income** | -$2.82M |
| Interest Income | $8.76M |
| **Net Income** | $5.94M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Income** | -$96K | -$137K | -$143K | -$2.09M | -$264K | -$132K | -$331K | -$145K |
| Interest Income | $1.34M | $1.86M | $2.11M | $2.30M | $2.45M | $2.42M | $1.59M | -- |
| **Net Income** | $1.24M | $1.73M | $1.97M | $213K | $2.18M | $2.29M | $1.25M | -$145K |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $6.1K | $1.4K |
| **Cash & Short-Term Investments** | $6.1K | $1.4K |
| **Total Current Assets** | $12K | $5.0K |
| **Total Non-Current Assets** | $239.9M | $546K |
| **Total Assets** | $239.9M | $551K |
| **Total Current Liabilities** | $376K | $796K |
| Deferred Revenue (Non-Current) | $6.90M | -- |
| **Total Non-Current Liabilities** | $6.90M | $0 |
| **Total Liabilities** | $7.28M | $796K |
| Common Stock | $1.1K | $986 |
| Retained Earnings | -$7.27M | -$280K |
| **Total Stockholders' Equity** | -$7.26M | -$245K |
| Total Equity | -$7.26M | -$245K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $17K | $20K | $15K | $6.1K | $717 | $822 | $923 | $1.4K |
| **Cash & Short-Term Investments** | $17K | $20K | $15K | $6.1K | $717 | $822 | $923 | $1.4K |
| **Total Current Assets** | $49K | $69K | $15K | $12K | $28K | $50K | $71K | $5.0K |
| **Total Non-Current Assets** | $147.4M | $146.8M | $242.0M | $239.9M | $237.6M | $235.2M | $232.7M | $546K |
| **Total Assets** | $147.5M | $146.9M | $242.0M | $239.9M | $237.6M | $235.2M | $232.8M | $551K |
| **Total Current Liabilities** | $2.26M | $2.94M | $492K | $376K | $457K | $301K | $347K | $796K |
| Deferred Revenue (Non-Current) | -- | -- | -- | $6.90M | -- | -- | -- | -- |
| **Total Non-Current Liabilities** | $6.19M | $6.19M | $6.90M | $6.90M | $6.90M | $6.90M | $6.90M | $0 |
| **Total Liabilities** | $8.45M | $9.14M | $7.39M | $7.28M | $7.36M | $7.20M | $7.25M | $796K |
| Common Stock | $1.1K | $1.1K | $1.1K | $1.1K | $1.1K | $1.1K | $1.1K | $986 |
| Retained Earnings | -$8.40M | -$7.41M | -$7.38M | -$7.27M | -$6.72M | -$6.46M | -$6.33M | -$280K |
| **Total Stockholders' Equity** | -$8.40M | -$7.41M | -$7.38M | -$7.26M | -$7.33M | -$7.15M | -$7.18M | -$245K |
| Total Equity | -$8.40M | -$7.41M | -$7.38M | -$7.26M | -$7.33M | -$7.15M | -$7.18M | -$245K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 |
| --- | --- |
| Net Income | $5.94M |
| **Operating Cash Flow** | -$539K |
| **Investing Cash Flow** | -$231.2M |
| **Financing Cash Flow** | $231.7M |
| **Net Change in Cash** | $4.8K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | $1.24M | $1.73M | $1.97M | $213K | $2.18M | $2.29M | $1.25M | -$145K |
| **Operating Cash Flow** | -$78K | -$245K | -$91K | -$125K | -$56K | -$107K | -$251K | -- |
| **Investing Cash Flow** | -- | -- | -- | $0 | $0 | $0 | -$231.2M | -- |
| **Financing Cash Flow** | $975K | -$98.46M | $100K | $131K | $56K | $107K | $231.4M | -- |
| **Net Change in Cash** | -$3.3K | $5.4K | $8.8K | $5.4K | -$105 | -$101 | -$428 | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 |
| --- | --- |
| Return on Assets (ROA) | 2.5% |
| Current Ratio | 0.03x |
| Quick Ratio | 0.02x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Assets (ROA) | 3.5% | 4.1% | 2.8% | 2.5% | -- | -- | -- | -- |
| Current Ratio | 0.02x | 0.02x | 0.03x | 0.03x | 0.06x | 0.16x | 0.20x | -- |
| Quick Ratio | 0.01x | 0.01x | 0.03x | 0.02x | 0.00x | 0.00x | 0.00x | -- |
| **Net Income Growth (YoY)** | -43.0% | -24.5% | +57.1% | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
